Hexarelin

Overview

Hexarelin (also known as examorelin; development code EP-23905) is a synthetic hexapeptide that belongs to the family of growth-hormone-releasing peptides (GHRPs). It acts as an agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a), the same receptor targeted by GHRP-2, GHRP-6, and the endogenous hormone ghrelin. First described in the early 1990s, hexarelin was characterized as a potent stimulator of growth hormone (GH) release in both animals and humans.

Two features give hexarelin its particular place in the research literature. First, it is a strong GH releaser, reported in early work to be at least as potent as, and in some comparisons more potent than, GHRP-6. Second, beyond the GH axis, hexarelin has been studied for a distinct cardiovascular action mediated by the CD36 receptor that appears to be independent of growth hormone release. Unlike the more selective secretagogue Ipamorelin, hexarelin also raises cortisol/ACTH and prolactin, and its GH response tends to desensitize with continued use.

Hexarelin reached early-phase human clinical investigation (including studies relevant to GH-deficiency diagnosis and to heart failure), but development was not completed and it has never received marketing approval from the FDA, EMA, or any other major regulator for any indication.

Chemistry and structure

Hexarelin is a short, fully synthetic peptide. Its defining structural feature is the 2-methylation of the D-tryptophan residue at position 2, a modification that increases metabolic stability and receptor-binding affinity relative to earlier GHRPs.

The sequence incorporates D-configured and modified residues (D-2-methyl-Trp and D-Phe) that distinguish hexarelin from naturally occurring peptides and contribute to its stability. Unlike endogenous ghrelin, a 28-residue peptide bearing an essential octanoyl (acyl) modification, hexarelin is a small synthetic mimetic that requires no acylation to activate the receptor.

Mechanism of action

Hexarelin's actions involve two distinct receptor interactions.

1. GHS-R1a (the GH-releasing pathway). Hexarelin binds and activates the GHS-R1a receptor expressed in the anterior pituitary and the hypothalamus. Activation on pituitary somatotrophs promotes the release of stored growth hormone, producing a pulse of GH secretion. This is the same receptor and broad mechanism used by other GHRPs and is distinct from growth-hormone-releasing hormone (GHRH) analogs such as CJC-1295 and Sermorelin, which act on the separate GHRH receptor. Because the two pathways are complementary, GHRPs and GHRH analogs are frequently studied together. Hexarelin has also been shown in animal models to up-regulate the expression of its own GHS-R1a receptor at hypothalamic and pituitary sites in an age-dependent fashion.

2. CD36 (a growth-hormone-independent cardiac pathway). Photoaffinity-labeling work in rat cardiac membranes identified the receptor mediating hexarelin's cardiovascular action as CD36, a multifunctional scavenger-receptor glycoprotein expressed in cardiomyocytes and microvascular endothelium, not the classic GHS-R1a. This pathway is the basis for hexarelin's distinctive cardiovascular research interest and is considered separate from its GH-releasing activity.

A clinically relevant feature is that, unlike selective agents, hexarelin's GHS-R1a activity is accompanied by stimulation of the ACTH/cortisol axis and prolactin (discussed below).

Research and evidence

It is important to separate the relatively extensive animal and early pharmacology data from the more limited human clinical evidence. No large, long-term, controlled human trials support hexarelin for anti-aging, body composition, or athletic-performance uses.

Growth hormone and hormonal responses (human)

• Dose-response (Massoud et al., 1996). Intravenous hexarelin in healthy men released GH, prolactin, and cortisol in a dose-dependent manner, establishing that, unlike selective secretagogues, hexarelin meaningfully engages the prolactin and cortisol axes.
• Age-related variation (Arvat et al., 1997). GH and ACTH responses to hexarelin differed across age groups, while cortisol responses did not vary significantly by age.
• Chronic administration (Rahim et al., 1999). Over 16 weeks of twice-daily dosing, problematic over-stimulation of the pituitary-adrenal axis and prolactin did not occur, and the cortisol response actually declined over time, consistent with attenuation of the hormonal response with continued exposure.

Cardiovascular and CD36 research (largely animal/preclinical)

• Cardioprotection in GH-deficient rats (De Gennaro Colonna et al., 1997). In rats with isolated GH deficiency, hexarelin reversed signs of cardiac and endothelial dysfunction.
• CD36 as the cardiac receptor (Bodart et al., 2002). This study identified the cardiac binding protein for hexarelin as CD36 and showed that activating it in perfused hearts produced dose-dependent cardiovascular effects — the mechanistic basis for hexarelin's growth-hormone-independent cardiac action. Much of the supporting cardioprotection data (for example, reductions in ischemia-reperfusion injury) comes from animal models, including studies using CD36-knockout animals to confirm the receptor's role.

These cardiovascular findings are preclinical and mechanistic; they have not translated into an approved cardiac therapy in humans.

Animal pharmacology

• GH-releasing activity (Deghenghi et al., 1994). Early rat work characterized hexarelin as a highly effective GH releaser, with subcutaneous administration producing long-lasting GH release and a profile slightly more effective than GHRP-6 in some comparisons.

Safety and risks

Human safety data are limited to small early-phase studies, and long-term safety in humans is not established. Several class-specific considerations are relevant:

• Cortisol and prolactin elevation. Unlike the selective agent Ipamorelin, hexarelin raises cortisol/ACTH and prolactin along with GH (Massoud et al., 1996). Elevated prolactin and cortisol are physiologically meaningful and are generally considered undesirable off-target effects of the less selective GHRPs.
• Desensitization (tachyphylaxis). The GH response to hexarelin tends to diminish with continued or repeated dosing. Cellular studies have reported rapid desensitization of the receptor's calcium response after an initial dose, and human chronic-dosing data show attenuation of hormonal responses over weeks — a recognized limitation of GHRPs as long-term GH stimulators.
• GH/IGF-1 axis effects. As a GH secretagogue, raising GH/IGF-1 signaling carries class-level theoretical concerns (for example, effects on glucose handling, fluid retention, or unmasking of occult conditions).
• Product quality. Material sold as "hexarelin" in the research-chemical market is not subject to pharmaceutical quality control; purity, identity, and sterility cannot be assumed.

This section is descriptive, not a safety endorsement. No dosing guidance is provided.

Regulatory and legal status

• Approval. Hexarelin has no marketing approval from the FDA, EMA, or any comparable national regulator for any indication. Although it reached early-phase human clinical investigation (including work relevant to GH-deficiency diagnosis and heart failure), development was not completed and it is not a recognized prescription medication. It is distributed as a research chemical / laboratory reagent.
• Anti-doping (sport). Hexarelin is prohibited at all times (in and out of competition) under the World Anti-Doping Agency (WADA) Prohibited List, within Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which explicitly covers growth hormone secretagogues and ghrelin-receptor agonists/mimetics. Athletes in WADA-governed sport must not use it.
• General. Regulatory and legal status varies by country; the absence of approval means there is no legitimate human-therapeutic channel for it in most jurisdictions.

How it compares

Hexarelin sits among the ghrelin-receptor agonists (GHRPs) and is best understood by contrast with its relatives:

• GHRP-2 and GHRP-6 act on the same GHS-R1a receptor and, like hexarelin, are less selective: they also stimulate cortisol and prolactin (and GHRP-6 notably stimulates appetite). Hexarelin is generally regarded as among the more potent GH releasers of the group.
• Ipamorelin is the more selective agent: it releases GH while largely sparing ACTH, cortisol, and prolactin. This is the key practical distinction — hexarelin trades selectivity for potency and engages the cortisol/prolactin axes.
• CD36 distinction. Hexarelin's growth-hormone-independent CD36-mediated cardiac action is a feature emphasized in its research literature and is not the defining property of the more selective ipamorelin.

None of these ghrelin-agonist peptides is approved for human use. Hexarelin's distinctions are its potency and its CD36/cardiac research angle, not a stronger human evidence base. See the Muscle & growth hormone overview for how these GH-axis agents relate.

Common misconceptions